Nuventra Pharma Sciences is now Allucent. Learn more here.

Take a deeper dive


Webinar | Pharmacogenomics and Pediatric Drug Development: When Are Children Not Little Adults and Why?

This event has passed. See all of our upcoming events, browse our Webinar Library for past presentations or, check out our Resource Library for blogs, case studies, news, toolkits and more. 

Join us on Wednesday, December 2nd from 1:00pm – 2:00pm EST for a webinar on how ontogeny and pharmacogenomics influence drug disposition in infants and children. Nuventra’s senior consultant, Gregory L. Kearns, PharmD, PhD, FAAP, will lead the session titled, “Pharmacogenomics and Pediatric Drug Development: When Are Children Not Little Adults and Why?

This webinar will cover an introduction of the intersection of ontogeny and pharmacogenomics as it relates to differences in drug biotransformation and pharmacokinetics in pediatrics. At the end of this webinar attendees should have a better understanding of:

  • The concept of “developmental trajectory” in the context of drug biotransformation
  • How ontogeny and pharmacogenomics contribute to variability in pediatric pharmacokinetics
  • The relevance of developmental maturation to allometric scaling (to scale or not to scale) as a tool for pediatric dose selection

Meet the Presenter

Gregory L. Kearns, PharmD, PhD, FAAP
Senior Consultant, Clinical Pharmacology

Dr. Kearns has more than 35 years of scientific experience in pediatric clinical pharmacology and toxicology.  He has extensive expertise in the design, conduct and analyses of early phase clinical trials of pediatric medicines with a focus on the impact of development and pharmacogenomics on drug disposition (PK) and action (PD).  Dr. Kearns’ therapeutic area experience includes infectious disease, gastrointestinal disease, allergic disease/asthma and the development of biomarkers to assess pharmacodynamics in infants and children. His regulatory experience includes service on several FDA advisory committees, consultancies with EMEA and 12 years of ongoing service as a member of the World Health Organization Committee on the Selection and Use of Essential Medicines.